44 followers
RT @MDuruisseaux: We calibrated the model and the efficacy of the treatments using public data, available in the literature, including the…
689 followers
We calibrated the model and the efficacy of the treatments using public data, available in the literature, including the results of the FLAURA study (https://t.co/CNMj7kKpfY) and the WJOG8515L study. (https://t.co/VbCt5Javmx). (4/9)
905 followers
A Randomized Phase II Study Comparing Nivolumab with Carboplatin013Pemetrexed for EGFR-Mutated NSCLC with ... https://t.co/htHJ5SVChp
6,874 followers
RT @StephenVLiu: Randomized phase II compared nivolumab to carbo/pem chemotherapy in #EGFR mutant NSCLC post TKI (WJOG8515L) now @CCR_AACR.…
2,071 followers
RT @StephenVLiu: Randomized phase II compared nivolumab to carbo/pem chemotherapy in #EGFR mutant NSCLC post TKI (WJOG8515L) now @CCR_AACR.…
516 followers
RT @StephenVLiu: Randomized phase II compared nivolumab to carbo/pem chemotherapy in #EGFR mutant NSCLC post TKI (WJOG8515L) now @CCR_AACR.…
1,067 followers
RT @StephenVLiu: Randomized phase II compared nivolumab to carbo/pem chemotherapy in #EGFR mutant NSCLC post TKI (WJOG8515L) now @CCR_AACR.…
2,005 followers
RT @StephenVLiu: Randomized phase II compared nivolumab to carbo/pem chemotherapy in #EGFR mutant NSCLC post TKI (WJOG8515L) now @CCR_AACR.…
1,954 followers
RT @StephenVLiu: Randomized phase II compared nivolumab to carbo/pem chemotherapy in #EGFR mutant NSCLC post TKI (WJOG8515L) now @CCR_AACR.…
1,719 followers
RT @StephenVLiu: Randomized phase II compared nivolumab to carbo/pem chemotherapy in #EGFR mutant NSCLC post TKI (WJOG8515L) now @CCR_AACR.…
272 followers
RT @StephenVLiu: Randomized phase II compared nivolumab to carbo/pem chemotherapy in #EGFR mutant NSCLC post TKI (WJOG8515L) now @CCR_AACR.…
826 followers
RT @StephenVLiu: Randomized phase II compared nivolumab to carbo/pem chemotherapy in #EGFR mutant NSCLC post TKI (WJOG8515L) now @CCR_AACR.…
27,536 followers
Can we get immunotherapy to work for TKI resistant EGFR or ALK patients? We need to keep working on it. Here is another study where immunotherapy alone is not successful. https://t.co/7OqTyODhYc
1,111 followers
RT @StephenVLiu: Randomized phase II compared nivolumab to carbo/pem chemotherapy in #EGFR mutant NSCLC post TKI (WJOG8515L) now @CCR_AACR.…
1,418 followers
RT @StephenVLiu: Randomized phase II compared nivolumab to carbo/pem chemotherapy in #EGFR mutant NSCLC post TKI (WJOG8515L) now @CCR_AACR.…
792 followers
RT @StephenVLiu: Randomized phase II compared nivolumab to carbo/pem chemotherapy in #EGFR mutant NSCLC post TKI (WJOG8515L) now @CCR_AACR.…
23,968 followers
Randomized phase II compared nivolumab to carbo/pem chemotherapy in #EGFR mutant NSCLC post TKI (WJOG8515L) now @CCR_AACR. Nivolumab RR 9.6%, mPFS 1.7m while chemo RR 36%, mPFS 5.6m. This is an old study (began 2016) and does not need repeating. https://t
7,428 followers
A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L) https://t.co/UWpQTA6w6c
29 followers
RT @weoncologists: Just out in @CCR_AACR Phase2️⃣WJOG8515L finds In #EGFR mutated #NSCLC w resistance to TKI Nivo🧪doesnt🚫confer longer PF…
6,874 followers
(PK)-tumor growth dynamics model developed by Grisic et al mechanistically captures the prevention of loss of antitumor immunity by #avelumab in patients with metastatic #MerkelCellCarcinoma. https://t.co/8fSm5iXSGC https://t.co/YfcHxlse42
192 followers
Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated #NSCLC with Resistance to #EGFR Tyrosine Kinase Inhibitors. https://t.co/i2HBGSmeCl
16,470 followers
RT @OncoAlert: Out on @CCR_AACR 🚨 In #EGFR mutated #NSCLC w resistance to TKI Nivo doesnt confer longer PFS🆚carboplatin-pemetrexed🧪
28 followers
A Randomized Phase 2 Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L) | Clinical Cancer Research https://t.co/kKq7rEW12N
155 followers
RT @CCR_AACR: Study by Hayashi et al show no survival benefit for metastatic EGFR-mutated #NSCLC patients treated with #nivolumab vs standa…
6,874 followers
Study by Hayashi et al show no survival benefit for metastatic EGFR-mutated #NSCLC patients treated with #nivolumab vs standard #chemotherapy. Some patients had a favorable tumor immune microenvironment that was associated with nivolumab efficacy. https://
6,874 followers
RT @OncoAlert: Out on @CCR_AACR 🚨 In #EGFR mutated #NSCLC w resistance to TKI Nivo doesnt confer longer PFS🆚carboplatin-pemetrexed🧪 https…
6,874 followers
RT @weoncologists: Just out in @CCR_AACR Phase2️⃣WJOG8515L finds In #EGFR mutated #NSCLC w resistance to TKI Nivo🧪doesnt🚫confer longer PF…
34 followers
A Randomized Phase 2 Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L) https://t.co/ZkwnriFMla
23,474 followers
RT @weoncologists: Just out in @CCR_AACR Phase2️⃣WJOG8515L finds In #EGFR mutated #NSCLC w resistance to TKI Nivo🧪doesnt🚫confer longer PF…
494 followers
RT @weoncologists: Just out in @CCR_AACR Phase2️⃣WJOG8515L finds In #EGFR mutated #NSCLC w resistance to TKI Nivo🧪doesnt🚫confer longer PF…
16,470 followers
RT @weoncologists: Just out in @CCR_AACR Phase2️⃣WJOG8515L finds In #EGFR mutated #NSCLC w resistance to TKI Nivo🧪doesnt🚫confer longer PF…
910 followers
RT @OncoAlert: Out on @CCR_AACR 🚨 In #EGFR mutated #NSCLC w resistance to TKI Nivo doesnt confer longer PFS🆚carboplatin-pemetrexed🧪
34,686 followers
RT @OncoAlert: Out on @CCR_AACR 🚨 In #EGFR mutated #NSCLC w resistance to TKI Nivo doesnt confer longer PFS🆚carboplatin-pemetrexed🧪
907 followers
RT @OncoAlert: Out on @CCR_AACR 🚨 In #EGFR mutated #NSCLC w resistance to TKI Nivo doesnt confer longer PFS🆚carboplatin-pemetrexed🧪
1,111 followers
RT @OncoAlert: Out on @CCR_AACR 🚨 In #EGFR mutated #NSCLC w resistance to TKI Nivo doesnt confer longer PFS🆚carboplatin-pemetrexed🧪
139 followers
RT @weoncologists: Just out in @CCR_AACR Phase2️⃣WJOG8515L finds In #EGFR mutated #NSCLC w resistance to TKI Nivo🧪doesnt🚫confer longer PF…
2,946 followers
RT @OncoAlert: Out on @CCR_AACR 🚨 In #EGFR mutated #NSCLC w resistance to TKI Nivo doesnt confer longer PFS🆚carboplatin-pemetrexed🧪
3,793 followers
RT @weoncologists: Just out in @CCR_AACR Phase2️⃣WJOG8515L finds In #EGFR mutated #NSCLC w resistance to TKI Nivo🧪doesnt🚫confer longer PF…
272 followers
RT @weoncologists: Just out in @CCR_AACR Phase2️⃣WJOG8515L finds In #EGFR mutated #NSCLC w resistance to TKI Nivo🧪doesnt🚫confer longer PF…
155 followers
RT @weoncologists: Just out in @CCR_AACR Phase2️⃣WJOG8515L finds In #EGFR mutated #NSCLC w resistance to TKI Nivo🧪doesnt🚫confer longer PF…
1,954 followers
RT @OncoAlert: Out on @CCR_AACR 🚨 In #EGFR mutated #NSCLC w resistance to TKI Nivo doesnt confer longer PFS🆚carboplatin-pemetrexed🧪
257 followers
A Randomized Phase 2 Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L) https://t.co/JqMariaLm2
906 followers
New article: A Randomized Phase 2 Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L) https://t.co/yfUmF8se3t #lungcancer #oncology https://t.co/nwim7coiBc
155 followers
RT @weoncologists: Just out in @CCR_AACR Phase2️⃣WJOG8515L finds In #EGFR mutated #NSCLC w resistance to TKI Nivo🧪doesnt🚫confer longer PF…
2,946 followers
RT @weoncologists: Just out in @CCR_AACR Phase2️⃣WJOG8515L finds In #EGFR mutated #NSCLC w resistance to TKI Nivo🧪doesnt🚫confer longer PF…
2,913 followers
RT @OncoAlert: Out on @CCR_AACR 🚨 In #EGFR mutated #NSCLC w resistance to TKI Nivo doesnt confer longer PFS🆚carboplatin-pemetrexed🧪
2,439 followers
RT @weoncologists: Just out in @CCR_AACR Phase2️⃣WJOG8515L finds In #EGFR mutated #NSCLC w resistance to TKI Nivo🧪doesnt🚫confer longer PF…
689 followers
RT @weoncologists: Just out in @CCR_AACR Phase2️⃣WJOG8515L finds In #EGFR mutated #NSCLC w resistance to TKI Nivo🧪doesnt🚫confer longer PF…
857 followers
RT @weoncologists: Just out in @CCR_AACR Phase2️⃣WJOG8515L finds In #EGFR mutated #NSCLC w resistance to TKI Nivo🧪doesnt🚫confer longer PF…
34,686 followers
RT @weoncologists: Just out in @CCR_AACR Phase2️⃣WJOG8515L finds In #EGFR mutated #NSCLC w resistance to TKI Nivo🧪doesnt🚫confer longer PF…
804 followers
RT @OncoAlert: Out on @CCR_AACR 🚨 In #EGFR mutated #NSCLC w resistance to TKI Nivo doesnt confer longer PFS🆚carboplatin-pemetrexed🧪 https…
1,571 followers
RT @weoncologists: Just out in @CCR_AACR Phase2️⃣WJOG8515L finds In #EGFR mutated #NSCLC w resistance to TKI Nivo🧪doesnt🚫confer longer PF…
34,686 followers
16,470 followers
7,428 followers
A Randomized Phase 2 Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L) https://t.co/2Muzl9Zf5r